ATRC - AtriCure Inc Stock Price, Fair Value and News

23.59USD+0.14 (+0.60%)Delayed as of 18 Apr 2024, 10:49 am ET

Market Summary

USD23.59+0.14

Delayedas of 18 Apr 2024, 10:49 am

0.60%

ATRC Stock Price

View Fullscreen

ATRC RSI Chart

ATRC Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-36.66

Price/Sales (Trailing)

2.8

EV/EBITDA

-81.13

Price/Free Cashflow

-148.51

ATRC Price/Sales (Trailing)

ATRC Profitability

Operating Margin

75.23%

EBT Margin

-7.48%

Return on Equity

-6.53%

Return on Assets

-4.96%

Free Cashflow Yield

-0.67%

ATRC Fundamentals

ATRC Revenue

Revenue (TTM)

399.2M

Rev. Growth (Yr)

21.03%

Rev. Growth (Qtr)

8.4%

ATRC Earnings

Earnings (TTM)

-30.4M

Earnings Growth (Yr)

-134.75%

Earnings Growth (Qtr)

-8.11%

Breaking Down ATRC Revenue

52 Week Range

22.9059.61

(Low)(High)

Last 7 days

-9.5%

Last 30 days

-26.6%

Last 90 days

-29.0%

Trailing 12 Months

-43.7%

How does ATRC drawdown profile look like?

ATRC Financial Health

Current Ratio

3.57

Debt/Equity

0.13

Debt/Cashflow

0.07

ATRC Investor Care

Shares Dilution (1Y)

2.20%

Diluted EPS (TTM)

-0.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	349.3M	365.7M	380.7M	399.2M
2022	289.6M	302.8M	315.6M	330.4M
2021	212.6M	243.1M	258.8M	274.3M
2020	230.1M	212.0M	210.1M	206.5M
2019	208.6M	215.7M	222.4M	230.8M
2018	180.4M	187.0M	194.8M	201.6M
2017	160.4M	166.0M	169.8M	174.7M
2016	135.8M	142.9M	149.8M	155.1M
2015	112.5M	118.6M	123.3M	129.8M
2014	87.3M	93.4M	99.9M	107.5M
2013	72.2M	74.4M	78.4M	81.9M
2012	66.2M	67.7M	68.6M	70.2M
2011	60.7M	63.3M	64.0M	64.4M
2010	0	56.0M	57.5M	59.0M
2009	0	0	0	54.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AtriCure Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	noznesky justin j	sold	-45,585	30.39	-1,500	chief mktg & strategy officer
Mar 18, 2024	dahlquist karl s.	sold	-60,621	32.16	-1,885	chief legal officer
Mar 14, 2024	carrel michael h	gifted	-	-	-2,000	president, ceo, & director
Mar 12, 2024	noznesky justin j	sold	-55,080	36.72	-1,500	chief mktg & strategy officer
Mar 05, 2024	dahlquist karl s.	sold	-307,510	37.36	-8,231	chief legal officer
Mar 01, 2024	yount deborah lee	sold (taxes)	-	-	-2,056	chief human resources officer
Mar 01, 2024	seith douglas j	sold (taxes)	-529,543	36.28	-14,596	chief operating officer
Mar 01, 2024	noznesky justin j	acquired	-	-	28,622	chief mktg & strategy officer
Mar 01, 2024	privitera salvatore	acquired	-	-	26,427	chief technical officer
Mar 01, 2024	carrel michael h	sold (taxes)	-1,735,050	36.28	-47,824	president, ceo, & director

Which funds bought or sold ATRC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	WEST PACES ADVISORS INC.	unchanged	-	-131	761	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	sold off	-100	-357	-	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	5,889	5,889	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	new	-	842,421	842,421	-%
Apr 05, 2024	CWM, LLC	reduced	-41.77	-3,000	3,000	-%
Apr 03, 2024	Versant Capital Management, Inc	new	-	213	213	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	2.25	-43,882	219,137	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	new	-	2,028,940	2,028,940	0.01%
Mar 11, 2024	VANGUARD GROUP INC	added	1.62	-35,317,300	170,100,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	193	14,780,700	25,382,800	-%

Are Funds Buying or Selling ATRC?

Are funds buying ATRC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATRC

No. of Funds

Unveiling AtriCure Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alliancebernstein l.p.	7.2%	3,394,036	SC 13G/A
Feb 13, 2024	vanguard group inc	10.06%	4,766,029	SC 13G/A
Feb 01, 2024	invesco ltd.	2.5%	1,162,050	SC 13G/A
Jan 25, 2024	blackrock inc.	8.8%	4,193,887	SC 13G/A
Dec 08, 2023	vanguard group inc	10.01%	4,745,971	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	7.7%	3,565,726	SC 13G/A
Feb 14, 2023	alger associates inc	3.8%	1,755,398	SC 13G/A
Feb 09, 2023	vanguard group inc	9.44%	4,389,815	SC 13G/A
Feb 03, 2023	blackrock inc.	8.0%	3,735,766	SC 13G/A
Feb 03, 2023	invesco ltd.	7.2%	3,367,324	SC 13G/A

Recent SEC filings of AtriCure Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	DEF 14A	DEF 14A
Apr 03, 2024	DEFA14A	DEFA14A
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	PRE 14A	PRE 14A
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 12, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to AtriCure Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.83%	1.66%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.32%	-8.43%	53.41	3.44	4.02%	-22.04%
ALGN	22.6B	3.9B	-4.99%	-13.70%	50.69	5.84	3.42%	23.09%
BAX	20.1B	14.8B	-4.86%	-7.71%	7.56	1.35	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-0.64%	16.68%	32.12	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-5.34%	-15.09%	21.69	0.73	-2.44%	-22.68%
BIO	8.5B	2.7B	-12.68%	-39.24%	-13.34	3.18	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.94%	-25.15%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-1.55%	17.10%	-564.74	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-3.92%	-2.28%	11.91	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-5.32%	-19.06%	-1.85	0.39	7.73%	-1066.14%
ANIK	381.5M	166.7M	1.82%	-7.51%	-4.61	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	17.44%	-27.90%	-1.32	0.78	-3.19%	-337.41%
APYX	45.7M	52.3M	-25.42%	-56.00%	-2.44	0.87	17.61%	19.28%
AEMD	3.7M	3.7M	-14.97%	255.00%	-0.3	0.99	5.77%	8.23%

AtriCure Inc News

Latest updates

AtriCure Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	8.4%	106,543,000	98,290,000	100,918,000	93,494,000	88,028,000	83,246,000	84,529,000	74,576,000	73,218,000	70,460,000	71,376,000	59,275,000	57,725,000	54,757,000	40,824,000	53,225,000	61,321,000	56,614,000	58,906,000	53,966,000	52,893,000
Cost Of Revenue	9.4%	26,728,000	24,421,000	23,841,000	23,885,000	22,915,000	21,533,000	21,010,000	18,981,000	18,202,000	18,234,000	17,298,000	14,735,000	15,288,000	14,423,000	13,170,000	14,341,000	16,547,000	14,817,000	15,013,000	14,095,000	14,303,000
Gross Profit	8.0%	79,815,000	73,869,000	77,077,000	69,609,000	65,113,000	61,713,000	63,519,000	55,595,000	55,016,000	52,226,000	54,078,000	44,540,000	42,437,000	40,334,000	27,654,000	38,884,000	44,774,000	41,797,000	43,893,000	39,871,000	38,590,000
Operating Expenses	8.0%	88,483,000	81,958,000	81,221,000	75,391,000	69,249,000	72,436,000	77,179,000	69,745,000	67,518,000	-46,443,000	69,155,000	60,425,000	59,940,000	44,325,000	34,939,000	54,338,000	60,100,000	50,434,000	47,732,000	45,191,000	41,197,000
S&GA Expenses	9.9%	67,687,000	61,604,000	63,783,000	60,064,000	55,501,000	57,267,000	62,388,000	56,116,000	51,160,000	49,873,000	56,958,000	49,208,000	47,095,000	33,557,000	24,903,000	42,751,000	51,920,000	40,280,000	37,928,000	37,015,000	32,742,000
R&D Expenses	2.2%	20,796,000	20,354,000	17,438,000	15,327,000	13,748,000	15,169,000	14,791,000	13,629,000	13,808,000	11,284,000	12,197,000	11,217,000	10,871,000	10,576,000	10,036,000	11,587,000	13,096,000	10,154,000	9,804,000	8,176,000	8,455,000
EBITDA Margin	-48.7%	-0.03	-0.02	-0.03	-0.07	-0.10	-0.14	0.22	0.22	0.23	0.23	-0.18	-0.17	-	-	-	-	-	-	-	-	-
Interest Expenses	1.5%	1,798,000	1,772,000	1,719,000	1,636,000	1,561,000	1,324,000	1,101,000	1,000,000	1,083,000	1,449,000	1,197,000	1,189,000	1,194,000	1,232,000	1,231,000	1,228,000	1,257,000	1,113,000	879,000	862,000	1,320,000
Income Taxes	693.6%	373,000	47,000	93,000	78,000	121,000	46,000	45,000	56,000	53,000	38,000	66,000	31,000	98,000	-4,000	12,000	8,000	48,000	75,000	10,000	66,000	79,000
Earnings Before Taxes	-4.5%	-9,416,000	-9,008,000	-5,025,000	-6,398,000	-4,049,000	-12,226,000	-14,796,000	-15,127,000	-13,688,000	97,146,000	-16,185,000	-16,886,000	-18,464,000	-4,953,000	-8,224,000	-16,400,000	-16,048,000	-9,287,000	-4,091,000	-5,569,000	-3,351,000
EBT Margin	-16.3%	-0.07	-0.06	-0.08	-0.11	-0.14	-0.18	0.18	0.18	0.18	0.18	-0.23	-0.23	-	-	-	-	-	-	-	-	-
Net Income	-8.1%	-9,789,000	-9,055,000	-5,118,000	-6,476,000	-4,170,000	-12,272,000	-14,841,000	-15,183,000	-13,741,000	97,108,000	-16,251,000	-16,917,000	-18,562,000	-4,949,000	-8,236,000	-16,408,000	-16,096,000	-9,362,000	-4,101,000	-5,635,000	-3,430,000
Net Income Margin	-17.0%	-0.08	-0.07	-0.08	-0.11	-0.14	-0.18	0.18	0.18	0.18	0.18	-0.23	-0.23	-	-	-	-	-	-	-	-	-
Free Cashflow	159.0%	1,244,000	-2,108,000	-69,000	-6,581,000	-4,125,000	-6,929,000	45,000	-28,013,000	-2,409,000	-1,736,000	-8,746,000	-10,642,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.3%	614	600	594	583	585	582	587	585	615	613	701	700	715	708	704	528	558	561	343	338	357
Current Assets	5.4%	266	253	238	238	215	212	206	200	196	196	236	298	307	296	292	127	143	138	147	155	175
Cash Equivalents	4.6%	84.00	81.00	67.00	77.00	58.00	49.00	55.00	28.00	44.00	40.00	68.00	85.00	42.00	33.00	89.00	22.00	28.00	33.00	25.00	21.00	32.00
Inventory	9.7%	68.00	62.00	55.00	49.00	46.00	44.00	41.00	41.00	39.00	39.00	38.00	36.00	35.00	34.00	33.00	32.00	29.00	28.00	24.00	24.00	22.00
Net PPE	-	-	-	-	-	-	39.00	36.00	33.00	31.00	30.00	30.00	28.00	28.00	29.00	30.00	32.00	33.00	31.00	28.00	27.00	27.00
Goodwill	0%	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	235	236	105	105	105
Liabilities	7.5%	148	137	132	128	129	132	131	122	132	125	316	309	302	290	287	300	311	303	102	99.00	107
Current Liabilities	-9.7%	75.00	83.00	71.00	62.00	58.00	58.00	56.00	47.00	56.00	54.00	67.00	58.00	49.00	45.00	38.00	39.00	50.00	44.00	39.00	35.00	40.00
Long Term Debt	43.7%	61.00	42.00	47.00	52.00	57.00	60.00	60.00	60.00	60.00	56.00	44.00	49.00	53.00	50.00	54.00	58.00	60.00	60.00	34.00	33.00	36.00
LT Debt, Non Current	43.7%	61.00	42.00	47.00	52.00	57.00	60.00	60.00	60.00	60.00	56.00	44.00	49.00	53.00	50.00	54.00	58.00	60.00	60.00	34.00	33.00	36.00
Shareholder's Equity	0.7%	466	463	462	455	457	450	457	463	484	488	385	391	412	418	417	227	247	258	242	239	249
Retained Earnings	-2.8%	-357	-347	-338	-333	-326	-322	-310	-295	-280	-266	-363	-347	-330	-311	-306	-298	-282	-266	-256	-252	-247
Additional Paid-In Capital	1.5%	824	812	803	791	787	778	771	762	765	755	749	738	742	729	724	526	530	525	498	492	497
Shares Outstanding	0.3%	48.00	47.00	47.00	47.00	47.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,276	-	-	-	1,852	-	-	-	3,556	-	-	-	1,961	-	-	-	1,111	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	164.8%	4,030	1,522	3,011	-4,079	46.00	-1,784	4,229	-24,632	301	-232	-4,533	-9,316	3,954	3,812	-11,548	-16,087	-3,529	-2,590	3,746	-13,438	985
Share Based Compensation	7.5%	9,312	8,661	8,995	8,760	7,197	7,001	7,524	7,049	7,539	6,794	7,141	6,604	6,516	5,549	6,193	4,384	5,161	4,287	4,375	4,154	4,829
Cashflow From Investing	-123.5%	-2,786	11,870	-16,080	28,813	7,002	-3,239	20,521	19,722	1,077	-25,101	-16,059	63,587	-1,980	-58,737	-112,812	17,331	-2,601	-9,633	-930	11,017	-70,826
Cashflow From Financing	1687.1%	2,359	132	2,994	-5,517	1,982	-405	1,861	-10,497	2,507	-2,260	2,818	-10,707	6,453	-301	191,074	-7,834	1,354	20,293	1,696	-8,970	84,129

ATRC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 399,245	$ 330,379	$ 274,329
Cost of revenue	98,875	84,439	68,469
Gross profit	300,370	245,940	205,860
Operating expenses (benefit):
Research and development expenses	73,915	57,337	48,506
Selling, general and administrative expenses	253,138	231,272	204,649
Change in fair value of contingent consideration (Note 2)	0	0	(184,800)
Intangible asset impairment (Note 4)	0	0	82,300
Total operating expenses	327,053	288,609	150,655
(Loss) income from operations	(26,683)	(42,669)	55,205
Other income (expense):
Interest expense	(6,925)	(4,986)	(4,918)
Interest income	3,792	1,994	466
Other	(31)	(537)	(366)
(Loss) income before income tax expense	(29,847)	(46,198)	50,387
Income tax expense	591	268	188
Net (loss) income	$ (30,438)	$ (46,466)	$ 50,199
Net (loss) income per share:
Basic net (loss) income per share (in usd per share)	$ (0.66)	$ (1.02)	$ 1.11
Diluted net (loss) income per share (in usd per share)	$ (0.66)	$ (1.02)	$ 1.09
Weighted average shares outstanding:
Weighted average shares outstanding, basic (in shares)	46,309	45,740	45,066
Weighted average shares outstanding, diluted (in shares)	46,309	45,740	46,039
Comprehensive (loss) income:
Unrealized gain (loss) on investments	$ 2,898	$ (2,811)	$ (941)
Foreign currency translation adjustment	205	(337)	(319)
Other comprehensive income (loss)	3,103	(3,148)	(1,260)
Net (loss) income	(30,438)	(46,466)	50,199
Comprehensive (loss) income, net of tax	$ (27,335)	$ (49,614)	$ 48,939

ATRC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 84,310	$ 58,099
Short-term investments	52,975	63,014
Accounts receivable, less allowance for credit losses of $500 and $230	52,501	42,693
Inventories	67,897	45,931
Prepaid and other current assets	8,563	5,477
Total current assets	266,246	215,214
Assets, Noncurrent
Long-term investments	0	51,509
Property and equipment, net	42,435	38,833
Operating lease right-of-use assets	4,324	3,787
Intangible assets, net	63,986	39,339
Goodwill	234,781	234,781
Other noncurrent assets	2,160	1,985
Total Assets	613,932	585,448
Current liabilities:
Accounts payable	27,354	19,898
Accrued liabilities	44,682	33,022
Current maturities of debt and leases	2,533	5,472
Total current liabilities	74,569	58,392
Long-term debt	60,593	56,834
Finance lease liabilities	8,061	9,147
Operating lease liabilities	3,307	3,095
Other noncurrent liabilities	1,234	1,226
Total Liabilities	147,764	128,694
Commitments and contingencies (Note 10)
Stockholders’ Equity:
Common stock, $0.001 par value, 90,000 shares authorized; 47,526 and 46,563 issued and outstanding	48	47
Additional paid-in capital	824,170	787,422
Accumulated other comprehensive loss	(993)	(4,096)
Accumulated deficit	(357,057)	(326,619)
Total Stockholders’ Equity	466,168	456,754
Total Liabilities and Stockholders’ Equity	$ 613,932	$ 585,448

About AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

CEO	Mr. Michael H. Carrel
WEBSITE	atricure.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1050

AtriCure Inc Frequently Asked Questions

What is the ticker symbol for AtriCure Inc? What does ATRC stand for in stocks?

ATRC is the stock ticker symbol of AtriCure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AtriCure Inc (ATRC)?

As of Wed Apr 17 2024, market cap of AtriCure Inc is 1.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRC stock?

You can check ATRC's fair value in chart for subscribers.

What is the fair value of ATRC stock?

You can check ATRC's fair value in chart for subscribers. The fair value of AtriCure Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AtriCure Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATRC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AtriCure Inc a good stock to buy?

The fair value guage provides a quick view whether ATRC is over valued or under valued. Whether AtriCure Inc is cheap or expensive depends on the assumptions which impact AtriCure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRC.

What is AtriCure Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, ATRC's PE ratio (Price to Earnings) is -36.66 and Price to Sales (PS) ratio is 2.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AtriCure Inc's stock?

In the past 10 years, AtriCure Inc has provided 0.037 (multiply by 100 for percentage) rate of return.